Civil Society Monitoring of Hepatitis C Response Related to the WHO 2030 Elimination Goals in 35 European Countries

M Maticic (prof.maticic@gmail.com)
University of Ljubljana  https://orcid.org/0000-0003-4261-0424

Z Pirnat
Clinic for Infectious Diseases and febrile Illnesses, University of Ljubljana

A Leicht
Fixpunkt e.V.

R Zimmermann
Robert Koch Institut

T Windelinckx
Free Clinic

M Jauffret-Roustide
Cermes3

E Duffell
European Centre for Disease Prevention and Control

T Tammi
National Institute for Health and Welfare Kiban Kenko Eiyo Kenkyujo

E Schatz
Correlation - European Harm Reduction Network  https://orcid.org/0000-0003-1636-790X

Research

Keywords: hepatitis C, people who inject drugs, continuum-of-care, harm reduction, civil society, monitoring

DOI: https://doi.org/10.21203/rs.3.rs-87395/v1

License: ☑️ Ⓟ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

People who inject drugs (PWID) account for the majority of new cases of hepatitis C virus (HCV) infection in Europe, however HCV testing and treatment for PWID remain suboptimal. With the advent of direct acting antivirals (DAAs) the World Health Organization (WHO) adopted a strategy to eliminate HCV as public health threat by 2030. To achieve this, key policies for PWID must be implemented and HCV continuum-of-care needs to be monitored. This study presents results of the first monitoring led by civil society that provide harm reduction services for PWID.

Methods

In 2019, harm reduction civil society organisations representing focal points of Correlation-European Harm Reduction Network in 36 European countries were invited to complete a 27-item online survey on four strategic fields: use/impact of guidelines on HCV testing and treatment for PWID, availability/functioning of continuum-of-care, changes compared to the previous year and, the role of harm reduction services and non-governmental organisations (NGOs) of PWID. A descriptive analysis of the responses was undertaken.

Results

The response rate was 97.2%. Six countries reported having no guidelines on HCV treatment (17.1%). Twenty-three (65.7%) reported having treatment guidelines with specific measures for PWID; guidelines that impact on accessibility to HCV testing/treatment and improve access to harm reduction services in 95.6% and 86.3% of them, respectively. DAAs were available in 97.1% of countries; in 26.4% of them they were contraindicated for active drug users. HCV screening/confirmatory tests performed at harm reduction services/community centres, prisons and drug dependence clinics were reported from 80.0%/25.7%, 60.0%/48.6%, and 62.9%/34.3% of countries, respectively. Provision of DAAs at drug dependence clinics and prisons was reported from 34.3% and 42.9% of countries, respectively. Compared to the previous year, HCV awareness campaigns, testing and treatment on service providers’ own locations were reported to increase in 42.9%, 51.4% and 42.9% of countries, respectively. NGOs of PWID conducted awareness campaigns on HCV interventions in 68.9% of countries, and 25.7% of countries had no such support.

Conclusion

Further improvements of continuum-of-care interventions for PWID are needed, which could be achieved by including harm reduction and PWID organisations in strategic planning of testing and treatment and in efforts to monitor progress towards WHO 2030 elimination goal.

Introduction

People who inject drugs (PWID) account for the majority of new cases of hepatitis C virus (HCV) infection in high income countries (1). Globally, 8.5% of the estimated 71 million HCV infections occur among persons aged 15-64 years who injected drugs within the last 12 months (1). In the WHO European region, it is estimated that 75% of two million of HCV actively infected PWID live in Eastern European countries. In available national studies, the prevalence of anti-HCV antibodies among PWID varies widely from 15% in the Czech Republic to 82% in Portugal (2) and it was estimated that in 2015, 16% of all people living with acute or chronic HCV infection in the European Union (EU) and Norway were PWID (3, 4). Among the four countries collecting data on the prevalence of viraemic HCV infections in PWID including acute and chronic ones, the prevalence in 2017 ranged from 26.7% in England and Wales to 65.1% in Vienna (5).

Chronic HCV infection causes liver damage that may proceed to cirrhosis, end-stage liver disease and hepatocellular carcinoma (6). Several studies have shown that treatment with direct acting antivirals (DAAs) in PWID is as effective as in the general population. Evidence already exists that aside of harm reduction programs, unrestricted and immediately accessible DAAs can lower the HCV prevalence among PWID (7, 8). However, in the last decade, due to ageing of HCV chronically infected PWID with
untreated HCV infection and late presentation, the mortality from HCV infection has increased particularly in this marginalised group, and deaths from liver disease are now as common as deaths from overdose in PWID over 50 years of age (9, 10).

In 2016, the World Health Organization (WHO) adopted a strategy to eliminate hepatitis C as a public health threat with targets aiming for a 65% decrease in mortality from HCV infection and a 90% decrease of new chronic HCV infections by the year 2030 (9). To achieve this goal the countries need to implement key policies and set up an appropriate healthcare system, particularly taking account of the needs of PWID. However, HCV testing and treatment for PWID remain suboptimal and a majority of them lacks access to harm reduction services, in spite of evidence based recommendations from WHO, the European Association for the Study of the Liver (EASL) (11) as well as other professional associations to assure PWID’s access to HCV testing and care as a matter of priority for individual as well as public health. The availability of hepatitis care varies substantially among countries and often remains below WHO targets, with globally less than 1% of PWID living in countries with access to both, HCV testing and treatment (12-14). Moreover, even where the services exist, PWID face many difficulties in accessing a continuum-of-care for hepatitis C that includes prevention, testing, linkage-to-care and treatment and are often excluded from treatment by restrictive guidelines, have poor access to health services, and suffer from universal stigmatization when disclosing their status as drug users (14).

To follow up the current situation and document progress made towards the 2030 WHO goal, the key policies, particularly for PWID, and a continuum-of-care should be carefully monitored. WHO Europe and the European Centre for Disease Prevention and Control (ECDC) have been working closely with experts in European countries on the monitoring system to help countries assess progress towards eliminating hepatitis C (15) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has developed an “elimination barometer”, which brings together available data on 17 PWID-specific indicators, matching the WHO’s monitoring and evaluation framework (3).

To better understand the barriers and opportunities to HCV testing and treatment in PWID, a much greater involvement of first line service providers such as the harm reduction agencies as well as the drug user community in the development of HCV policy and practice is needed (16). In order to contribute to the European monitoring efforts from a civil society perspective, in 2018 the Correlation-European Harm Reduction Network (C-EHRN) collected the experiences of civil society organisations (CSO) providing harm reduction services on interventions in the HCV continuum-of-care and best practice examples (17, 18). Furthermore, C-EHRN also conducted a telephone survey on the legal barriers for providing HCV community testing in Europe (19).

In 2019, C-EHRN introduced a novel and complementary monitoring tool in support of European level monitoring of progress towards the WHO elimination goals. This tool aims to collect the experiences of CSOs that provide harm reduction services on the availability and access of interventions that constitute the HCV continuum-of-care. The analysis of the results of this first monitoring is presented in this article.

**Materials And Methods**

In 2019, a cross-sectional prospective survey was performed by the C-EHRN. It was prepared, conducted and analysed through multiple rounds of consultation with and input from the members of a multidisciplinary Hepatitis C study group of the C-EHRN, which included the C-EHRN board and an international team of advisers, composed of clinicians, epidemiologists, sociologists, public health specialists, CSO managers and others.

**Data collection scope**

Respondents invited for the monitoring were harm reduction CSOs coming from 36 European countries where C-EHRN has its focal points. Scotland was treated separately from the rest of the United Kingdom (UK) due to the autonomous system for HCV management; the UK data therefore excluded the data from Scotland. Compared to EMCDDA reports (2, 3), the C-EHRN network brings information from additional nine countries which are not members of the EU (Albania, Bosnia and Herzegovina, Georgia, Montenegro, Russia, Serbia, Switzerland, Ukraine, and North Macedonia), however no contributions were available from four EMCDDA reporting countries (Cyprus, Estonia, Malta, Turkey).
Participants were invited to join the survey by completing an online questionnaire distributed to respondents via email and/or online. One questionnaire was completed per country. Data was collected by C-EHRN between June and September 2019. After the data collection was achieved, the responses were reviewed and analysed by the Hepatitis C study group of C-EHRN. In case of unclear, incomplete or inconsistent responses the respondents were asked via email to recheck them. If repeatedly giving unclear information respondents were contacted by phone to obtain a clarification and/or validate the meaning of their response.

The questionnaire

A 27-item online questionnaire was designed for the purpose of this survey (Appendix). The questionnaire addressed four strategic fields: the use and impact of guidelines on the accessibility to HCV testing and treatment for PWID; the availability and functioning of a continuum-of-care in different countries and regions; changes in continuum-of-care services compared to the previous year; and, the role of harm reduction services and non-governmental organisations (NGOs) of PWID in this context.

The definition of PWID used in this study included three different groups: “active PWID” referred to those who had injected drugs within the past six months (13); “PWID on Opioid Substitution Therapy (OST)” referred to those who are currently included in an OST program and are either not injecting anymore or are still occasionally injecting drugs; and “former PWID” referred to those who completely stopped injecting drugs.

The answers to most of the questions were binary (“yes” / “no”), however some questions had multiple-choice answer options. Furthermore, a free-text box was offered which respondents could use to add comments to clarify their answers and to provide additional qualitative information, links and other sources. The questionnaire was administered in English since no language barriers were expected from C-EHRN focal points respondents.

Data analysis

A descriptive and geospatial analysis was performed by the Hepatitis Study group of the C-EHRN. For every question and all the respondents the counts summaries and frequencies were performed. The comments in the boxes were analysed separately and in case of several similar comments or description of unusual practices or particularities, these are described in the paper.

Results

Out of 36 invited C-EHRN focal points, all except one (from Estonia) responded (35/36, 97.2%).

The use of guidelines for hepatitis C treatment in people who inject drugs

Among respondents, six (17.1%) reported on still having no national guidelines for HCV treatment and seven (20.0%) reported on using the ones from EASL (Figure 1).

Figure 1. Reported use of most relevant guidelines for the treatment of hepatitis C from 35 European countries and their indications for treatment in different groups of people who inject drugs. Scotland was treated separately from the rest of the United Kingdom. The countries in white did not participate in the study. The countries in blue use the national guidelines; the countries in grey use the guidelines of the European Association for the Study of the Liver (EASL); the countries in green reported no guidelines. The coloured circles represent permission for treatment in different groups of people who inject drugs: former injectors only (red), former injectors plus those on opioid substitution treatment (OST) (yellow), former injectors plus those on OST plus active injectors (dark blue). In North Macedonia treatment for hepatitis C is not available at all.

In only 23 of the responding countries (65.7%) the guidelines used include specific measures for PWID. In all but one of those 23 countries the guidelines somehow impact the accessibility to HCV testing and treatment of PWID, however they impact better access to harm reduction service in only 19/22 countries. Qualitative responses showed that several respondents were pessimistic about the impact of the guidelines used in their country on better access of PWID to the services such as testing and treatment and even by their own agencies. Responses received indicated that even if national guidelines exist, they have a limited relevance in practice. A range of challenges was reported, such as outdated guidelines and complicated testing and treatment systems, as well as lack of services and other kinds of disproportions between the formal guidelines and the real-life situation.
However, as stated by some of the respondents, harm reduction agencies did not necessarily need official guidelines to start interventions on HCV.

According to the respondents, the DAAs were available in all reporting countries but North Macedonia (34/35, 97.1%). However, from 11/34 countries (32.4%) an official policy on restrictions for the use of DAAs was reported (Albania, Croatia, Finland, Latvia, Luxembourg, Montenegro, Romania, Russia, Serbia, Sweden, Ukraine). In 10 out of 34 countries (29.4%) DAAs were reported to be accessible only for people presenting liver fibrosis; in two countries (2/34, 5.9%) only advanced fibrosis or cirrhosis represented indications for DAA treatment (Albania, Serbia).

In 9/34 countries (26.4%) active drug users were still not applicable for DAA treatment (Figure 1). With the exception of Russia, PWID on OST were allowed to get HCV treatment in all other countries (33/34, 97.1%); former injectors were allowed DAA treatment in all of the included countries where DAAs were available (34/34, 100%).

All but six respondents (28/34, 82.3%) assessed that DAAs were being used in practice as stated in the official policy documents. DAA treatment was reimbursed by the health insurance or public health services in all countries except the UK; however, in a few countries the treatment was not automatically reimbursed for PWID (Hungary, Romania, and Serbia).

The functioning of a continuum-of-care for people who inject drugs

The C-EHRN monitoring data on a continuum-of-care including HCV testing and treatment showed that within Europe, a variety of service options existed for PWID, with some good and some bad practice examples (Table 1).

Respondents reported that screening tests for the detection of anti-HCV antibodies included either saliva testing (oral swabs) or blood testing (finger prick), whereas detection of HCV RNA was used as a confirmatory test. In the majority of countries the screening tests were a standard of care also outside the medical settings, such as harm reduction services or community centres (28/35, 80.0%) and prisons (21/35, 60.0%), as well as drug dependence clinics (22/35, 62.9%). The confirmatory testing was much more commonly performed at the infectious disease clinics (30/35, 85.7%) and gastroenterology clinics (18/35, 51.4%) compared to other settings, such as drug dependence clinics (12/35, 34.3%) and harm reduction services (9/35, 25.7%), however it was performed in prisons in 17/35 (48.6%) countries.

The prioritised settings for DAA treatment were the two clinical settings, infectious diseases and gastroenterology (29/35, 82.9% and 24/35, 68.6%, respectively). General practitioners (GPs) performed screening and confirmatory testing in 18/35 (51.4%) and 16/35 (45.7%) countries, respectively whereas they were allowed to prescribe DAA treatment in only 6/35 (17.1%) countries (the Czech Republic, Finland, France, Georgia, Germany, Scotland). DAA treatment was provided at the drug dependence clinics in 12/35 (34.3%) countries, and it was also provided in prisons in 15/35 (42.9%) countries. Since May 2019, all the physicians in France were allowed to prescribe DAAs.

Pharmacies were very rarely used as a setting for HCV testing (Italy, Scotland, and the UK) and DAA treatment (Scotland).

Scotland was reported to be the only country that offered HCV screening and confirmatory testing as well as DAA treatment at all the settings mentioned above.

Table 1. Settings for hepatitis C testing and treatment, as reported from 35 European countries. Scotland was treated separately from the rest of the United Kingdom.
| Country | Gastro-enterology clinics | Infectious disease clinics | Drug dependence clinics | Harm reduction services or community centres | General practitioner | Pharmacy | Prison |
|---------|--------------------------|---------------------------|------------------------|---------------------------------------------|----------------------|----------|--------|
| Albania | A R Y                     | A R Y                      | A N N                  | A N na                                      | N N N N A N          | N N N N | A N    |
| Austria | A R Y                     | N N A R                   | N A N                  | A N na                                      | A R N N N A R N      | N N N A | A Y    |
| Belgium | A R Y                     | A R N                     | A N A                  | A N na                                      | A N N N A Y          | N N N A | A N    |
| Bosnia and Herzegovina | N Y A R | N A | A N | A na | N N N N A N | N N N N | A N |
| Bulgaria | R Y N N | N N A R | N A | A na | N N N N | N N N N | N |
| Croatia | A R Y A R Y | A N A | A na | A R N N | N N A R | N N |
| Czech Republic | A R Y A R Y | A Y A | A na | R Y N N | A R Y | |
| Denmark | N N A R Y | A R N | A N | A na | A R N N | N N N N | N |
| Finland | R Y A R Y | A R Y | A R na | A R Y N | N N A R Y | |
| France | A R Y A R Y | A Y A | A na | A R Y N | N N A R Y | |
| Georgia | A Y A R Y | A Y A R na | A Y N N | A Y | |
| Germany | R Y A R Y | N Y A R na | A R Y N N | A R Y | |
| Greece | N N R N N N N | A na | N N N Y | N N | |
| Hungary | N Y R Y N N A na | N N N N | A R N | |
| Ireland | R Y R Y R Y | N na | R N N N | R Y | |
| Italy | N N R Y A N | A na | N N A N | A N | A R Y | |
| Latvia | N N R Y N N A | A na | R N N N | R Y | |
| Luxembourg | N N A R Y | A N N na | A N N N | A N | |
| Montenegro | N N R Y N N | N na | N N N N | N N | |
| Macedonia, North | N Y R Y N N | N na | N N N N | N N | |
| Netherlands | A R Y A R Y | A N N na | A R N N | A R N | |
| Norway | A Y N N N N na | A R N N | N N N | N N | |
| Poland | N N R Y A N | A na | A N N N | A Y | |
| Portugal | A R Y A R Y | A R Y A R na | R N N N | A R Y | |
| Romania | R Y R Y A N | A na | A N N N | A N | |
| Russia | N N A R Y A N | A na | N N N N | N N | |
| Scotland | A R Y A R Y | A R Y A R na | A R Y A R Y | A R Y | |
| Serbia | N N N Y N N A | A na | N N N N | N N | |
| Slovakia | R Y N Y R N A na | N N N N | N N R N | |
| Slovenia | N Y R Y R N | R na | R N N N | R N | |
A antibody test, R RNA test, N no, Y yes, na not analysed

#Testing included either screening test for hepatitis C virus antibodies (A) or confirmatory test for hepatitis C virus RNA (R), or both (AR)

##Treatment in harm reduction services and community centres was not included in the questionnaire

Eighteen countries (18/35, 51.4%) reported having precise linkage-to-care protocols/guidelines for newly HCV diagnosed PWID to be referred for treatment. The government monitored the numbers/proportions of people who progress through each stage of the HCV continuum-of-care on the national level in 14/35 countries (40.0%); monitoring at the regional or local level was performed in five and seven countries, respectively whereas in the remaining countries monitoring was not performed at al.

Longitudinal evaluation of a continuum-of-care

The current C-EHRN survey revealed the dynamic of providers’ investment in various services of a continuum-of-care. Compared to the previous year, 15/35 countries (42.9%) reported on having more attention paid to HCV awareness campaigns, 18/35 (51.4%) to testing on the service providers’ own locations, and 15/35 (42.9%) to treatment on the service providers’ own locations; 9/35 (25.7%) countries reported on improvements made in all the three services (Belgium, Denmark, Italy, the Netherlands, Poland, Romania, Scotland, Switzerland, Ukraine) (Figure 2). In other countries the situation had remained the same as in the previous year or there had been even less activities but overall compared to the previous year the results on changes made in the continuum-of-care were positive.

Figure 2. Improvements in a continuum-of-care compared to the previous year and the role of harm reduction and non-governmental organisations of people who inject drugs reported from 35 European countries. NGO non-governmental organisation, PWID people who inject drugs. #Scotland was treated separately from the rest of the United Kingdom. The countries in white did not participate in the study. ##The coloured circles represent improvements in a continuum-of-care compared to the previous year with regard to awareness campaigns (yellow), testing (blue) and treatment (red). ###The countries in blue report on having active non-governmental organisations of people who inject drugs; the countries in green report on having no such active non-governmental organisations; for the countries in rose the data are missing.

Role of harm reduction and non-governmental organisations of people who inject drugs

Twenty-four European countries (24/35, 68.6%) reported on having NGOs of PWID that are working actively for political awareness in regard of HCV interventions whereas no such NGO support is reported from nine countries (9/35, 25.7%) (Austria, Bosnia and Herzegovina, the Czech Republic, Finland, Hungary, Luxembourg, Romania, Scotland, Serbia) (Figure 2). Finally, while trying to address HCV among PWID the barriers and limitations repeatedly mentioned by the harm reduction organisations were the lack of funding, political support and general recognition of harm reduction measures (Albania, Germany, France, Hungary, Ireland, North Macedonia, Romania, Serbia, and the UK). The shortage of knowledge and training on HCV infection, as well as a lack of skilful staff were mentioned by the Czech Republic, France, Germany, Ireland and Russia. Another reported barrier was the weakness of the CSO, whereas legal barriers, particularly those regarding the possibility of testing within the community were reported from Greece and Montenegro.

Discussion
To date, globally, there exists no uniquely standardised protocol or system to monitor and evaluate the progress made towards the elimination of hepatitis C as a public health threat as set out in 2016 by the WHO Global Health Sector Strategy on Hepatitis that includes also a CSO perspective.

In Europe, the first report of the ECDC monitoring the progress towards HCV elimination in 2019 by collecting data from a range of existing sources in 31 countries of EU/European Economic Area (EEA) highlighted significant gaps in the availability of data related to the continuum-of-care such as prevention, testing and treatment. The report showed that overall, 27 countries provided data for at least one of the key stages of the HCV continuum-of-care, whereas only 11 countries were able to provide data along the continuum (15). The conclusion was that countries in the EU/EEA were not on track for meeting the WHO 2030 elimination targets.

From another perspective, the 2018 study of the European Liver Patient Association (ELPA) including patient groups from 25 European countries focused on the qualitative implementation of WHO recommendations and verification of policies to eliminate viral hepatitis in each of the examined countries (20). The results of the study revealed that generally the European region was not on track to meet WHO 2030 HCV goals, and presented some concerning discrepancies among the studied countries as well as overlooked opportunities for high-risk populations in many settings.

For the high-risk population of PWID, in 2019 the EMCDDA established an elimination barometer for hepatitis C helping EU countries, Norway and Turkey to assess their progress towards eliminating HCV among PWID (3). The current results revealed a high burden of HCV among PWID with information gaps in several countries, absence of systematic collection of data on HCV continuum-of-care for PWID, missed opportunities to HCV diagnosing and various restrictions to treatment with DAAs.

C-EHRN monitoring data presented here constitute the first results of civil society-led monitoring, reflecting the perspective of harm reduction service providers in 35 European countries evaluating the 2019 HCV treatment guideline situation and progress made between the years 2018 and 2019 in HCV interventions for PWID. It gathered responses on three key stages of a HCV continuum-of-care in PWID.

The data obtained revealed big differences within Europe as to where and how PWID could access testing for HCV. Even though incarcerated persons represent a high-risk population for HCV infection (21), HCV testing in prisons was reported only from 21 countries, representing a missed opportunity to identify cases. In 2019 DAAs were available in all countries of the region except North Macedonia; however PWID were still not allowed access to HCV treatment in 10 European countries. These results reveal a persistent stigmatisation towards PWID within the medical system which impedes good access to HCV care for PWID at an individual level, but also favours transmission of HCV infection in the population. Although 23 countries reported having guidelines that included specific HCV management recommendations for PWID, many C-EHRN respondents were somewhat pessimistic about the impact of such guidelines on improving access to the HCV continuum-of-care in their country, especially to integrated test-and-treat services. However, if access to DAA treatment had been achieved, the costs were reimbursable by health insurance or through the public health service in all but one monitored country.

On a more positive note, 23 European countries reported PWID organisations working actively to increase political awareness concerning HCV interventions. Compared to 2018, more attention had been paid over the past year to HCV awareness campaigns, to testing at the service providers’ own premises, and to treatment at the service providers own site. However, several barriers to address HCV among PWID are reported to persist, such as a lack of funding, knowledge, recognition, political support and skilful staff as well as weakness of CSO and legal barriers.

The survey also revealed that the monitoring of people progressing through each stage of the HCV continuum-of-care was performed at the governmental level in less than half of the observed countries, one third of them reported existence of regional or local monitoring, whereas monitoring of any kind was not at all the practice in one quarter of the included countries.

The analysis of the C-EHRN monitoring for 2019 showed that PWID in particular were still in an unequal position regarding HCV testing and treatment in different European countries and often deprived of proper HCV interventions. When comparing the continuum-of-care situation, it becomes obvious that the integration of testing and treatment at one site is still too rarely the case.
In countries with progressive HCV treatment policies, NGOs of PWID have played a pivotal role in raising the issue with the public and advocating for the right of PWID to low threshold HCV testing and treatment.

Indeed, the overall reporting on progress between 2018 and 2019 can be considered positive as there has been more action taking place in several countries. However, to reduce the HCV-related disease burden among PWID and achieve the 2030 elimination goals in Europe, a radical change in the HCV response is still needed in many of the European countries monitored in this C-EHRN survey. National treatment guidelines that address the specific challenges to overcome barriers like stigmatization and criminalisation of PWID are still needed in Europe. Those recommendations should underline the necessity of unrestricted access to DAA treatment, improvements in the continuum-of-care and further development of single site testing and treatment services (22).

To improve the low uptake of HCV testing and treatment among PWID it is crucial to include harm reduction and drug user organisations in the continuum of services providing HCV management within every European country (23). In order to reduce hepatitis C incidence and prevalence among PWID, access to interventions such as low-threshold needle and syringe programmes (NSP), as well as OST are essential (10, 24). OST has proven to be effective for the prevention of HCV infection and combination of OST and high-coverage NSP can reduce HCV incidence by more than 70%. The evaluation framework for the WHO elimination strategy provides clear targets to countries regarding the scale of provision of these measures (10). The 2019 EMCDDA monitoring data show that only a small proportion of countries have achieved the 2020 target for coverage of NSP but the majority of countries with data have reached the 40% coverage target for OST (2). At the same time, according to a C-EHRN study from 2018 the level of readiness in harm reduction and community-based organisations in Europe to provide testing and treatment for PWID remains high, yet funding, the attitude of health services towards PWID and harm reduction services in general as well as legal and regulatory practices in many countries have a negative impact on PWID’s access to social and health support (18).

The most important limitation of this survey is the involvement of only one stakeholder group for information selected from the C-EHRN database of focal point harm reduction CSO. They were not necessarily profoundly familiar with their respective governments’ HCV policies however they were excellently familiar with the harm reduction and HCV activities in their local environment and represent therefore ‘real life experiences’. The validity of the responses was not cross-referenced with current, official policies, so there exists a possibility of some inaccuracies in respondents’ answers.

Conclusions

The results of 2019 C-EHRN civil-society led monitoring of hepatitis C policies and the hepatitis C continuum-of-care for PWID in 35 European countries show a substantial shortfall and variations and urge for more action. Despite progress reported from several countries, further improvements of the existing continuum-of-care interventions for PWID are needed, which may be achieved by including the harm reduction and drug user organisations in the strategic planning of a continuum of services for HCV testing and treatment. Therefore, the roles and responsibilities not only at every level of the health system, but also beyond it need to be defined with respect to their delivery of hepatitis services. The findings of the C-EHRN Monitoring may provide some important information by first line service providers to the WHO Global Health Sector Strategy. By involving all stakeholders in the monitoring and reporting of national responses, a significant step forward can be made towards the elimination of HCV as a public health threat by 2030, as set out in the WHO Global Health Sector Strategy on Hepatitis.

Abbreviations

C-EHRN: Correlation – European Harm Reduction Network

CSO: Civil society organisations

DAAs: Direct-acting antivirals

EASL: European Association for the Study of the Liver
Declarations

Ethics approval and consent to participate

The research presented involved no human subjects, human material or human data. Therefore, ethics committee approval was not required.

Consent for publication

Not applicable

Availability of data and material

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

No Funding was received.

Authors' contributions

ES, TT and MM carried out the conceptualisation, design and coordination of the study. MM drafted the manuscript and prepared the final manuscript. TT prepared the database of respondents, carried out the collection of data and performed the study analysis. ZP, MJR, AL, ED, RZ and ES provided input during finalization of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to express utmost gratitude to Dagmar Hedrich for her valuable contribution to setting up the monitoring system as well as her comments and suggestions during finalization of the manuscript.
Appendix

Questionnaire for civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals

References

1. World Health Organization (WHO). Global hepatitis report, 2017. Geneva, Switzerland: World Health Organization; 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/

2. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2019: Trends and Developments. Luxembourg: Publications Office of the European Union, 2019.

3. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Monitoring the elimination of viral hepatitis as a public health threat among people who inject drugs in Europe: the elimination barometer. Technical reports. Publications Office of the European Union, Luxembourg, 2019.

4. Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction 2019; 114(1): 150-66.

5. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug-related infectious diseases in Europe. Update from the EMCDDA expert network. Technical report. Publications Office of the European Union, Luxembourg, 2020.

6. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-62.

7. Macías J, Morano LE, Téllez F, Granados R, Rivero-Juárez A, Palacios R, et al. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. J Hepatol 2019; 71: 45-51.

8. Iversen J, Dore GJ, Catlett B, Cunningham P, Grebely J, Maher L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. J Hepatol 2019; 70: 33-9.

9. Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol 2013; 58: 31–7.

10. World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis. Geneva, Switzerland: World Health Organization, https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/

11. European Association for the Study of the Liver (EASL). Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018; 69: 461-511.

12. Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health 2017; 5: e1208-20.

13. Maticic M, Lombardi A, Mondelli UM, Colombo M. Elimination of Hepatitis C in Europe: Can WHO Targets Be Achieved? Clin Microbiol Infect 2020; 26(7): 818-23.

14. Maticic M, Zorman JV, Gregorcic S, Schatz E, Lazarus JV. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. Harm Reduct J 2019; 16: 32.

15. European Centre for Disease Prevention and Control. Monitoring the responses to hepatitis B and C epidemics in EU/EEA Member States, 2019. Stockholm: ECDC; 2020.

16. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, et al; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015; 26: 1028-38.

17. Schatz E, Perez Gayo R, Raulet I. Good practice examples of hepatitis C prevention, testing and treatment by harm reduction services in Europe. Amsterdam, The Netherlands: Correlation European Harm Reduction Network (C-EHRN), 2019. https://www.correlation-net.org/wp-content/uploads/2019/09/good-practice_example_web.pdf
18. Schatz E, Perez Gayo R, Raulet I. Hepatitis C interventions by organisations providing harm reduction services in Europe – analysis and examples. Amsterdam, The Netherlands: Correlation European Harm Reduction Network (C-EHRN), 2019. https://www.correlationnet.org/wp-content/uploads/2019/07/HepInterventions_FullReport_high.pdf

19. Farrell J, Schatz E. Legal Barriers for Providing HCV Community Testing in Europe. Briefing Paper. Amsterdam, The Netherlands: Correlation European Harm Reduction Network (C-EHRN), 2019. https://www.correlation-net.org/wp-content/uploads/2019/07/HCV-Testing-Barriers-Report_FINAL.pdf

20. Palayew A, Stumo SR, Cooke GS, Hutchinson SJ, Jauffret-Roustate M, Maticic M, et al. The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. PLoS ONE 2020: 15(7): e0235715.

21. Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment. World J Hepatol 2015; 7(21): 2323–30.

22. Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, et al. Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. Clin Infect Dis 2013; 57: S129-37.

23. Lazarus J, Pericas JM, Picchio C, Černoša J, Hoekstra M, Luhrman N, et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med 2019; 286(5): 503-25.

24. Platt L, Reed J, Minozzi S, Hagan H, French C, Jordan A, et al. Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. The Cochrane Database of Systematic Reviews 2016; 2017: CD012021.

Figures
Figure 1

Reported use of most relevant guidelines for the treatment of hepatitis C from 35 European countries and their indications for treatment in different groups of people who inject drugs.
Figure 2

Improvements in a continuum-of-care compared to the previous year and the role of harm reduction and non-governmental organisations of people who inject drugs reported from 35 European countries.